he early immune response in a person who has been vaccinated for COVID-19 can predict the level of protection they will have to the virus over time, according to analysis from Australian mathematicians, clinicians, and scientists, and published today in Nature Medicine.
2021-05-12 06:36:18 GMT2021-05-12 14:36:18(Beijing Time) Xinhua English
SYDNEY, May 12 (Xinhua) Australian researchers have worked out how to predict which patients will recover quickly from influenza (flu) and which will become severely ill from the infectious disease.
Their findings, based on four years of research, was published in Nature Communications on Tuesday.
Researchers from the Peter Doherty Institute for Infection and Immunity, Alfred Health and Monash University said the studies also have implications for understanding how the immune system responds to COVID-19. This influenza study was the blueprint for our COVID-19 research, said Doherty Institute laboratory leader Katherine Kedzierska, who is a renowned influenza immunologist.
Published today in
Nature Communications, the team from the Peter Doherty Institute for Infection and Immunity (Doherty Institute), Alfred Health and Monash University sought to understand which patients would recover quickly from influenza and which would become severely ill.
The four-year project took samples from patients hospitalised with influenza at up to five time points during their hospital stay, and 30 days after discharge. They analysed the breadth of the immune response, enabling them to describe the specific roles of several different types of immune cells, including killer and helper T cells, B cells and innate cells.
University of Melbourne Dr Oanh Nguyen, Research Fellow at the Doherty Institute, said two significant findings of the research include understanding the biomarkers that drive recovery and identifying four specific cytokines that cause serious inflammation during influenza virus infection.
Share this article
ZURICH, May 5, 2021 /PRNewswire/
Global leader in textile and materials innovation, HeiQ, launches HeiQ MetalliQ, a futuristic-looking, high-tech surgical mask that destroys all viruses and bacteria tested, up to 100% efficacy.
HeiQ MetalliQ Type IIR surgical mask with an antiviral copper coated surface that deactivates 97.79% SARS-CoV-2 in five minutes. (image from HeiQ)
HeiQ MetalliQ Type IIR surgical mask with an antiviral copper coated surface that deactivates 97.79% SARS-CoV-2 in five minutes. (image from HeiQ)
HeiQ MetalliQ doesn t only
look metallic. The mask with a patented design actually contains an ultra-thin pure copper coating applied via a high-tech vapor deposition process, called HeiQ MetalliX, which converts a minute amount of copper into vapour, allowing it to be deposited evenly to surround each fibre. HeiQ MetalliX is a patent-pending technology, created by HeiQ s innovation partner, Australian materials technology company, Xefco. St